Delta opioid receptors expressed in forebrain GABAergic neurons are responsible for SNC80-induced seizures

Behavioural Brain Research

Volumn 278, Issue , 2015, Pages 429-434

  Chu Sin Chung, Paul ^a   Boehrer, Annie ^a   Stephan, Aline ^a   Matifas, Audrey ^a   Scherrer, Grégory ^b   Darcq, Emmanuel ^c   Befort, Katia ^a   Kieffer, Brigitte L ^a,c  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b Department of Anesthesiology Perioperative and Pain Medicine Department of Molecular and Cellular Physiology Department of Neurosurgery ^*  (United States)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Biased agonism; Conditional knockout; Delta agonist; Delta opioid receptor; Epileptic seizure; In vivo

Indexed keywords

4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 METHOXYBENZYL] N,N DIETHYLBENZAMIDE; ADL 5859; ARM 390; DELTA OPIATE RECEPTOR; DELTA OPIATE RECEPTOR AGONIST; UNCLASSIFIED DRUG; 4 AMINOBUTYRIC ACID RECEPTOR; 4-(ALPHA-(4-ALLYL-2,5-DIMETHYL-1-PIPERAZINYL)-3-METHOXYBENZYL)-N,N-DIETHYLBENZAMIDE; BENZAMIDE DERIVATIVE; BENZOPYRAN DERIVATIVE; N,N-DIETHYL-4-(5-HYDROXYSPIRO(CHROMENE-2,4'-PIPERIDINE)-4-YL)BENZAMIDE; NARCOTIC ANALGESIC AGENT; PIPERAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ELECTROENCEPHALOGRAPHY; FACILITATION; FOREBRAIN; GABAERGIC SYSTEM; GABAERGIC TRANSMISSION; GENE TARGETING; GENOTYPE; KNOCKOUT MOUSE; MALE; MOUSE; NERVE CELL INHIBITION; NONHUMAN; PROTEIN EXPRESSION; RECEPTOR GENE; SEIZURE; ANIMAL; CHEMICALLY INDUCED; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; REACTION TIME;

ANALGESICS, OPIOID; ANIMALS; BENZAMIDES; BENZOPYRANS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROENCEPHALOGRAPHY; GABAERGIC NEURONS; GENE EXPRESSION REGULATION; MICE; MICE, KNOCKOUT; PIPERAZINES; PROSENCEPHALON; REACTION TIME; RECEPTORS, OPIOID, DELTA; SEIZURES;

EID: 84910044423     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2014.10.029     Document Type: Article

References (25)

1. Gaveriaux-Ruff C., Kieffer B.L. Delta opioid receptor analgesia: recent contributions from pharmacology and molecular approaches. Behav Pharmacol 2011, 22:405-414.
2. Pradhan A.A., Befort K., Nozaki C., Gaveriaux-Ruff C., Kieffer B.L. The delta opioid receptor: an evolving target for the treatment of brain disorders. Trends Pharmacol Sci 2011, 32:581-590.
3. Chu Sin Chung P., Kieffer B.L. Delta opioid receptors in brain function and diseases. Pharmacol Ther 2013, 140:112-120.
4. Hudzik T.J., Maciag C., Smith M.A., Caccese R., Pietras M.R., Bui K.H., et al. Preclinical pharmacology of AZD2327: a highly selective agonist of the delta-opioid receptor. J Pharmacol Exp Ther 2011, 338:195-204.
5. Comer S.D., Hoenicke E.M., Sable A.I., McNutt R.W., Chang K.J., De Costa B.R., et al. Convulsive effects of systemic administration of the delta opioid agonist BW373U86 in mice. J Pharmacol Exp Ther 1993, 267:888-895.
6. Broom D.C., Nitsche J.F., Pintar J.E., Rice K.C., Woods J.H., Traynor J.R. Comparison of receptor mechanisms and efficacy requirements for delta-agonist-induced convulsive activity and antinociception in mice. J Pharmacol Exp Ther 2002, 303:723-729.
7. Danielsson I., Gasior M., Stevenson G.W., Folk J.E., Rice K.C., Negus S.S. Electroencephalographic and convulsant effects of the delta opioid agonist SNC80 in rhesus monkeys. Pharmacol Biochem Behav 2006, 85:428-434.
8. Le Bourdonnec B., Windh R.T., Ajello C.W., Leister L.K., Gu M., Chu G.H., et al. Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide (ADL5859). J Med Chem 2008, 51:5893-5896.
9. Le Bourdonnec B., Windh R.T., Leister L.K., Zhou Q.J., Ajello C.W., Gu M., et al. Spirocyclic delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl) benzamide (ADL5747). J Med Chem 2009, 52:5685-5702.
10. Saitoh A., Sugiyama A., Nemoto T., Fujii H., Wada K., Oka J., et al. The novel delta opioid receptor agonist KNT-127 produces antidepressant-like and antinociceptive effects in mice without producing convulsions. Behav Brain Res 2011, 223:271-279.
11. Jutkiewicz E.M., Rice K.C., Traynor J.R., Woods J.H. Separation of the convulsions and antidepressant-like effects produced by the delta-opioid agonist SNC80 in rats. Psychopharmacology (Berlin) 2005, 182:588-596.
12. Jutkiewicz E.M., Baladi M.G., Folk J.E., Rice K.C., Woods J.H. The convulsive and electroencephalographic changes produced by nonpeptidic delta-opioid agonists in rats: comparison with pentylenetetrazol. J Pharmacol Exp Ther 2006, 317:1337-1348.
13. Crunelli V., Cope D.W., Terry J.R. Transition to absence seizures and the role of GABA(A) receptors. Epilepsy Res 2011, 97:283-289.
14. Le Merrer J., Becker J.A., Befort K., Kieffer B.L. Reward processing by the opioid system in the brain. Physiol Rev 2009, 89:1379-1412.
15. Lalonde R., Strazielle C. Brain regions and genes affecting myoclonus in animals. Neurosci Res 2012, 74:69-79.
16. Rezai X., Faget L., Bednarek E., Schwab Y., Kieffer B.L., Massotte D. Mouse delta opioid receptors are located on presynaptic afferents to hippocampal pyramidal cells. Cell Mol Neurobiol 2012, 32:509-516.
17. Erbs E., Faget L., Scherrer G., Kessler P., Hentsch D., Vonesch J.L., et al. Distribution of delta opioid receptor-expressing neurons in the mouse hippocampus. Neuroscience 2012, 221:203-213.
18. Chu Sin Chung P., Keyworth H.L., Martin-Garcia E., Charbogne P., Darcq E., Bailey A., et al. Delta opioid receptors expressed in forebrain GABAergic neurons are responsible for SNC80-induced seizures. Biol Psychiatry 2014, [in press].
19. Pitman R.K., Rasmusson A.M., Koenen K.C., Shin L.M., Orr S.P., Gilbertson M.W., et al. Biological studies of post-traumatic stress disorder. Nat Rev Neurosci 2012, 13:769-787.
20. Smith K.S., Rudolph U. Anxiety and depression: mouse genetics and pharmacological approaches to the role of GABA(A) receptor subtypes. Neuropharmacology 2012, 62:54-62.
21. Pradhan A.A., Becker J.A., Scherrer G., Tryoen-Toth P., Filliol D., Matifas A., et al. In vivo delta opioid receptor internalization controls behavioral effects of agonists. PLoS ONE 2009, 4:e5425.
22. Nozaki C., Le Bourdonnec B., Reiss D., Windh R.T., Little P.J., Dolle R.E., et al. delta-Opioid mechanisms for ADL5747 and ADL5859 effects in mice: analgesia, locomotion, and receptor internalization. J Pharmacol Exp Ther 2012, 342:799-807.
23. Loscher W., Honack D., Fassbender C.P., Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. III. Pentylenetetrazole seizure models. Epilepsy Res 1991, 8:171-189.
24. Huang R.Q., Bell-Horner C.L., Dibas M.I., Covey D.F., Drewe J.A., Dillon G.H. Pentylenetetrazole-induced inhibition of recombinant gamma-aminobutyric acid type A (GABA(A)) receptors: mechanism and site of action. J Pharmacol Exp Ther 2001, 298:986-995.
25. Pradhan A.A., Smith M.L., Kieffer B.L., Evans C.J. Ligand-directed signalling within the opioid receptor family. Br J Pharmacol 2012, 167:960-969.